What is HC Wainwright’s Estimate for InflaRx Q3 Earnings?

InflaRx N.V. (NASDAQ:IFRX) – Stock analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for InflaRx in a research note issued on Tuesday, September 2nd. HC Wainwright analyst M. Keller expects that the company will post earnings of ($0.13) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for InflaRx’s current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for InflaRx’s Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.73) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at ($0.71) EPS and FY2028 earnings at ($0.72) EPS.

Other analysts have also issued reports about the company. Raymond James Financial lowered InflaRx from a “strong-buy” rating to an “outperform” rating and set a $2.00 price objective for the company. in a report on Thursday, May 29th. Oppenheimer lowered their price objective on InflaRx from $6.00 to $3.00 and set an “outperform” rating for the company in a report on Thursday, May 29th. Five analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $6.20.

InflaRx Stock Up 5.1%

Shares of InflaRx stock opened at $1.65 on Thursday. The firm has a market cap of $110.76 million, a P/E ratio of -2.06 and a beta of 1.43. InflaRx has a fifty-two week low of $0.71 and a fifty-two week high of $2.82. The business has a 50-day moving average price of $0.96 and a 200 day moving average price of $1.14.

InflaRx (NASDAQ:IFRX) last announced its earnings results on Thursday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.24). The business had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.02 million.

Institutional Investors Weigh In On InflaRx

A number of institutional investors and hedge funds have recently modified their holdings of IFRX. Cubist Systematic Strategies LLC raised its stake in InflaRx by 33.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after purchasing an additional 7,616 shares during the period. XTX Topco Ltd acquired a new stake in InflaRx during the 1st quarter valued at $38,000. Concurrent Investment Advisors LLC acquired a new stake in InflaRx during the 2nd quarter valued at $65,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in InflaRx by 158.3% during the 2nd quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company’s stock valued at $118,000 after purchasing an additional 91,927 shares during the period. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in InflaRx during the 2nd quarter valued at $262,000. Institutional investors and hedge funds own 42.39% of the company’s stock.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.